P96 (Q)
Gender: Male and Female
Smoking habit: Non / Ex-smoker only
Pot smoking
18 - 65
BMI : 18.00 - 30.00
Food restrictions : Fast
Clinic stay
- 8 Apr (17:30) to 13 Apr (09:00)
Return visits
- 16 Apr (08:00)
- 23 Apr (08:00)
- 30 Apr (08:00)
- 7 May (08:00)
- 14 May (08:00)
- 21 May (08:00)
- 28 May (08:00)
- 11 Jun (08:00)
- 25 Jun (08:00)
- 9 Jul (08:00)
Participants must be available to stay at our clinic for all of the dates listed above and/or in the notes below. All clinic stays and return visits are mandatory. Times are subject to change.
Medication type
This drug is indicated in the treatment for myasthenia gravis (chronic neuromuscular weakness).
Notes
There may be additional visits
To be eligible, you will be required to receive vaccines against meningitis during the screening period (unless already vaccinated).
Weight: 50 kg < 110 kg.
Phase 1 study.
Administration mode: subcutaneous.
Six hours fasting before medical exam.
You will receive $100 after completing the medical exam.
Participants must be fasted prior to each dosing.
Blood volume: male 400ml / female 400ml (16 blood draws).
Your medical history and/or medication intake history may affect your participation on this study.
Please note that we are testing for drugs and alcohol during the medical evaluation.
This is preliminary information and changes could occur without notice